A clinical comparison of oxymorphone-acepromazine and butorphanol-acepromazine sedation in dogs.
Oxymorphone (0.2 mg/kg, maximum 4.5 mg) or butorphanol (0.2 mg/kg, maximum 4.5 mg), with acepromazine (0.05 mg/kg) and atropine (0.02 mg/kg), was administered intravenously to 106 healthy dogs undergoing radiographic examination of the pelvis. The dogs were returned to their owners after the examination and opioid reversal with naloxone (0.02 mg/kg intravenously, maximum 0.4 mg). Questionnaires were completed by the radiology staff and owners of the dogs, and results were coded by one person, all of whom were unaware of the treatment used. There was a lower incidence of temporary excitement upon injection and less panting in dogs sedated with butorphanol than with oxymorphone. There were no significant differences in degree of sedation, response to noise or manipulation, vocalization, defecation, heart rate, reversibility, sedation after reversal, or personality. Both forms of chemical restraint were satisfactory for radiographic examination of the pelvis, with no significant side effects in healthy dogs.
Dyson
D H
DH
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Canada.
Atilola
M
M
D000075:Acepromazine / Q000008:administration & dosage / Q000009:adverse effects; D000818:Animals; D002077:Butorphanol / Q000008:administration & dosage / Q000009:adverse effects; D004285:Dogs / Q000502:physiology*; D004338:Drug Combinations; D005260:Female; D007103:Immobilization; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D010111:Oxymorphone / Q000008:administration & dosage / Q000009:adverse effects; D011897:Random Allocation; D011795:Surveys and Questionnaires
D004338:Drug Combinations; D000075:Acepromazine; D010111:Oxymorphone; D002077:Butorphanol